East Bay cancer drug maker to cut 175 jobs, reduce real estate footprint

The company, which is also repurchasing up to $450 million in stock, has aggressively expanded in Alameda and outside Philadelphia in recent years, but last year faced push back from key investors around its spending.
Click here to view original post